You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

PARICALCITOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Paricalcitol, and when can generic versions of Paricalcitol launch?

Paricalcitol is a drug marketed by Amneal Pharms, Aurobindo Pharma Ltd, Bionpharma, Dr Reddys, Lotus Pharm Co Ltd, Marksans Pharma, Rising, Teva Pharms Usa, Accord Hlthcare, Amneal Pharms Co, Epic Pharma Llc, Eugia Pharma, Hikma Pharms, Hospira, and Sandoz. and is included in seventeen NDAs.

The generic ingredient in PARICALCITOL is paricalcitol. There are ten drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the paricalcitol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Paricalcitol

A generic version of PARICALCITOL was approved as paricalcitol by SANDOZ on July 27th, 2011.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PARICALCITOL?
  • What are the global sales for PARICALCITOL?
  • What is Average Wholesale Price for PARICALCITOL?
Drug patent expirations by year for PARICALCITOL
Drug Prices for PARICALCITOL

See drug prices for PARICALCITOL

Drug Sales Revenue Trends for PARICALCITOL

See drug sales revenues for PARICALCITOL

Recent Clinical Trials for PARICALCITOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Early Phase 1
Cedars-Sinai Medical CenterEarly Phase 1
Chengdu Suncadia Medicine Co., Ltd.Phase 3

See all PARICALCITOL clinical trials

Pharmacology for PARICALCITOL
Paragraph IV (Patent) Challenges for PARICALCITOL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZEMPLAR Injection paricalcitol 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials 020819 1 2008-11-28
ZEMPLAR Capsules paricalcitol 1 mcg and 2 mcg 021606 1 2008-10-14
ZEMPLAR Capsules paricalcitol 4 mcg 021606 1 2008-08-25

US Patents and Regulatory Information for PARICALCITOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira PARICALCITOL paricalcitol SOLUTION;INTRAVENOUS 201657-001 Oct 21, 2014 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys PARICALCITOL paricalcitol SOLUTION;INTRAVENOUS 204910-002 Aug 17, 2016 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz PARICALCITOL paricalcitol SOLUTION;INTRAVENOUS 091108-003 Jul 27, 2011 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising PARICALCITOL paricalcitol SOLUTION;INTRAVENOUS 203897-002 Nov 2, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal Pharms Co PARICALCITOL paricalcitol SOLUTION;INTRAVENOUS 206699-001 Mar 9, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.